Hedge Fund Activity
Several hedge funds changed their investments in Bristol-Myers Squibb recently. Global Assets Advisory bought new shares worth $5.16 million. Lincoln National Corp increased its stake by 7.7%, owning now $2.33 million. Chapin Davis Inc. raised its investment by 22.6% to $1.22 million. Sierra Summit Advisors also entered a new position worth $755,000. Accel Wealth Management increased its holdings by 19% to $268,000. Institutional investors and hedge funds own 76.41% of the stock.
Bristol-Myers Squibb Stock Overview
BMY stock opened at $52.19 today. The company has a current ratio of 1.16 and a debt-to-equity ratio of 2.86. Its market cap is $105.79 billion, with a P/E ratio of -16.84. Shares have fluctuated between a low of $39.35 and a high of $57.65 over the past year.
Earnings Report Highlights
On July 26, Bristol-Myers Squibb reported an EPS of $2.07 for the last quarter, exceeding expectations of $1.64. Revenue reached $12.20 billion, up 8.7% from last year.
Dividend Announcement
The company announced a quarterly dividend of $0.60, payable on November 1, for investors who are on the record by October 4. The annualized dividend is $2.40, yielding 4.60%.
Analyst Ratings
Recent reports show mixed analyst ratings: StockNews.com upgraded Bristol-Myers to “strong-buy,” while Deutsche Bank lowered its price target. Market consensus rates the stock as “Hold” with a target price of $53.00.
Company Overview
Bristol-Myers Squibb is a biopharmaceutical company involved in the discovery, development, and marketing of various treatments including for cancer and heart disease.
Featured Stories
- Five stocks we prefer over Bristol-Myers Squibb
- 2 Fintech Stocks to Buy and 1 to Avoid
- 3 Micro-Caps Set for Major Moves
See what other hedge funds hold BMY: Visit HoldingsChannel.com.
`
